natgillin/translations-raw huggingface dataset:
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Apidra 100 Units/ml solution for injection 
IME ZDRAVILA IN POT(I) UPORABE Apidra 100 enot/ml raztopina za injiciranje insulin glulisin
EU/1/04/285/030 3 pens of 3 ml. 
EU/1/04/285/030 3 injekcijski peresniki s 3 ml.
EU/1/04/285/031 4 pens of 3 ml. 
EU/1/04/285/005 1 vložek s 3 ml.
Look at the vial before you use it. Only use it if the solution is clear, colourless and has no visible particles in it. 
Uporabite ga le, če je raztopina bistra, brezbarvna in v njej ni vidnih delcev.
Apidra SoloStar 100 Units/ml solution for injection in a pre-filled pen. 
Apidra SoloStar 100 enot/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
Apidra 100 Units/ml solution for injection in a cartridge Apidra 100 Units/ml in cartridges is only suitable for subcutaneous injections from a reusable pen. 
Apidra 100 enot/ml raztopina za injiciranje v vložku Zdravilo Apidra 100 enot/ml v vložku je primerno samo za podkožno injiciranje z injekcijskim peresnikom za večkratno uporabo.
• Skin and subcutaneous tissue disorders 
• Kožne in alergijske reakcije na mestu injiciranja
The glucose-lowering activities of insulin glulisine and regular human insulin are equipotent when administered by intravenous route. 
Po intravenski uporabi sta insulin glulisin in navadni humani insulin glede tega učinka ekvipotentna.
Apidra 100 Units/ml solution for injection in a vial Solution for injection in a vial. 
FARMACEVTSKA OBLIKA Apidra 100 enot/ml raztopina za injiciranje v viali Raztopina za injiciranje v viali.
EU/1/04/285/005 1 cartridge of 3ml EU/1/04/285/006 3 cartridges of 3ml. 
EU/1/04/285/032 5 injekcijskih peresnikov s 3 ml. EU/1/04/285/033 6 injekcijskih peresnikov s 3 ml. EU/1/04/285/034 8 injekcijskih peresnikov s 3 ml. EU/1/04/285/035 9 injekcijskih peresnikov s 3 ml. EU/1/04/285/036 10 injekcijskih peresnikov s 3 ml.
The pen should be used as recommended in the information provided by the device manufacturer. 
Injekcijski peresnik morate uporabljati po navodilih izdelovalca.
Organ system classes 
Organski sistemi po MedDRA
Examples include: - you inject too much insulin, - you miss meals or delay them, - you do not eat enough, or eat food containing less carbohydrate than normal (sugar and substances similar to sugar are called carbohydrates; however, artificial sweeteners are NOT 
Primeri: - injicirate preveč insulina, - izpustite obroke ali jih imate prepozno, - ne jeste dovolj ali uživate hrano, ki vsebuje manj ogljikovih hidratov kot normalno (sladkor in sladkorju podobne snovi imenujemo ogljikovi hidrati; toda umetna sladila NISO ogljikovi hidrati), - izgubljate ogljikove hidrate zaradi bruhanja ali driske, - pijete alkohol (zlasti če ne jeste dosti), - ste bolj dejavni kot navadno ali je telesna dejavnost drugačna kot ponavadi, - okrevate po poškodbi, operaciji ali drugem stresu, - okrevate po bolezni ali po vročini, - uporabljate ali ste nehali uporabljati določena druga zdravila (glejte poglavje 2, "Uporaba drugih zdravil").
It is taken once a day with food. 
Jemlje se enkrat na dan s hrano.
The full EPAR for Tenofovir disoproxil Zentiva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Dizoproksiltenofovirat Zentiva je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
In adolescents (from 12 to 18 years of age) its use is only for those who cannot be treated with other first-line nucleotide reverse transcriptase inhibitors (NRTI). 
Njegova uporaba pri mladostnikih (starih med 12 in 18 let) je namenjena le tistim, ki jih ni mogoče zdraviti z drugimi nukleotidnimi zaviralci reverzne transkriptaze (NRTI) prve izbire.
This is a summary of the European public assessment report (EPAR) for Tenofovir disoproxil Zentiva. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Dizoproksiltenofovirat Zentiva.
In adults, it can also be used for those patients with liver damage whose liver does not work properly (decompensated liver disease) and those patients who do not respond to treatment with lamivudine (another medicine for hepatitis B). 
Pri odraslih se lahko uporablja tudi pri tistih bolnikih s poškodovanimi jetri, pri katerih ta ne delujejo pravilno (dekompenzirana jetrna bolezen), in tistih, ki se ne odzivajo na zdravljenje z lamivudinom (drugim zdravilom za zdravljenje okužbe z virusom hepatitisa B).
For more information on how the medicine is taken including doses for adults and adolescents, see the summary of product characteristics (also part of the EPAR). 
Za več informacij o jemanju zdravila, vključno z odmerjanjem za odrasle in mladostnike, glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
The company that markets Tenofovir disoproxil Zentiva will ensure that all doctors who are expected to prescribe or use the medicine are provided with educational materials containing important safety information, particularly on the risks and precautions relating to kidney function and the bones. 
Družba, ki trži zdravilo Dizoproksiltenofovirat Zentiva, bo zagotovila, da bodo vsi zdravniki, ki naj bi predpisovali ali uporabljali zdravilo Dizoproksiltenofovirat Zentiva, prejeli izobraževalno gradivo, ki bo vsebovalo pomembne varnostne informacije, zlasti o tveganjih in previdnostnih ukrepih, ki se nanašajo na delovanje ledvic in kosti.
The Committee recommended that Tenofovir disoproxil Zentiva be approved for use in the EU. 
Priporočil je, da se zdravilo Dizoproksiltenofovirat Zentiva odobri za uporabo v EU.
What measures are being taken to ensure the safe and effective use of Tenofovir disoproxil Zentiva? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Dizoproksiltenofovirat Zentiva?
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Tenofovir disoproxil Zentiva has been shown to have comparable quality and to be bioequivalent to Viread. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Dizoproksiltenofovirat Zentiva primerljivo raven kakovosti kot zdravilo Viread ter da mu je biološko enakovredno.
Tenofovir disoproxil Zentiva, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level. 
Zdravilo Dizoproksiltenofovirat Zentiva v kombinaciji z drugimi protivirusnimi zdravili zniža količino virusa HIV v krvi in jo vzdržuje na nizki ravni.
Tenofovir disoproxil Zentiva is available as tablets (245 mg) to be taken by mouth. 
Zdravilo Dizoproksiltenofovirat Zentiva je na voljo v obliki tablet (245 mg), ki se jemljejo peroralno.
Because Tenofovir disoproxil Zentiva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Dizoproksiltenofovirat Zentiva generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI). 
Tenofovir je zaviralec nukleotidne reverzne transkriptaze (NRTI).
This means that Tenofovir disoproxil Zentiva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Viread. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Viread.
Tenofovir disoproxil Zentiva is an antiviral medicine used to treat patients aged 12 years and above infected with human immunodeficiency virus type 1 (HIV 1), a virus that causes acquired immune deficiency syndrome (AIDS). 
Dizoproksiltenofovirat Zentiva je protivirusno zdravilo, ki se uporablja za zdravljenje bolnikov, starejših od 12 let, ki so okuženi z virusom človeške imunske pomanjkljivosti tipa 1 (HIV 1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (AIDS).
Tenofovir disoproxil Zentiva does not cure HIV infection or AIDS, but it can hold off damage to the immune system and avoid the development of infections and diseases associated with AIDS. 
Zdravilo Dizoproksiltenofovirat Zentiva ne ozdravi okužbe z virusom HIV ali AIDS-a, vendar pa lahko upočasni slabšanje imunskega sistema ter prepreči razvoj okužb in bolezni, povezanih z AIDS-om.
For patients who have taken medicines to treat HIV infection before, doctors should only prescribe Tenofovir disoproxil Zentiva once they have looked at the antiviral medicines the patient has taken before or the likelihood of the virus's response to antiviral medicines. 
Bolnikom, ki so predhodno že jemali zdravila za zdravljenje okužbe z virusom HIV, smejo zdravniki predpisati zdravilo Dizoproksiltenofovirat Zentiva šele potem, ko se seznanijo s protivirusnimi zdravili, ki jih je bolnik jemal pred tem, oziroma ko ocenijo, kakšna je verjetnost, da se bo virus odzval na protivirusna zdravila.
Tenofovir also interferes with the action of an enzyme produced by the hepatitis B virus called ‘DNA polymerase', which is involved in the formation of viral DNA. 
Tenofovir prav tako ovira delovanje encima, ki ga proizvaja virus hepatitisa B, imenovan „DNKpolimeraza“, ki je vključen v proces nastajanja virusne DNK.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tenofovir disoproxil Zentiva have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Dizoproksiltenofovirat Zentiva upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Tenofovir disoproxil Zentiva stops the virus making DNA and prevents it from multiplying and spreading. 
Zdravilo Dizoproksiltenofovirat Zentiva ustavi tvorbo DNK v virusu in tako prepreči njegovo razmnoževanje in širjenje.
Tenofovir disoproxil Zentiva can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of HIV infection or chronic hepatitis B. 
Predpisovanje in izdaja zdravila Dizoproksiltenofovirat Zentiva je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV ali kroničnega hepatitisa B.
What are the benefits and risks of Tenofovir disoproxil Zentiva? 
Kakšne so koristi in tveganja, povezani z zdravilom Dizoproksiltenofovirat Zentiva?
Tenofovir disoproxil Zentiva is also used to treat chronic (long-term) hepatitis B virus infection in adults and adolescents aged 12 years and above with liver damage whose liver is still able to work (compensated liver disease). 
Zdravilo Dizoproksiltenofovirat Zentiva se uporablja tudi za zdravljenje kronične (dolgotrajne) okužbe z virusom hepatitisa B pri odraslih in mladostnikih, starejših od 12 let, s poškodovanimi jetri, ki še delujejo pravilno (kompenzirano jetrno boleznijo).
For more information about treatment with Tenofovir disoproxil Zentiva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Dizoproksiltenofovirat Zentiva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What is Tenofovir disoproxil Zentiva and what is it used for? 
Kaj je zdravilo Dizoproksiltenofovirat Zentiva in za kaj se uporablja?
Because Tenofovir disoproxil Zentiva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Viread. 
Ker je zdravilo Dizoproksiltenofovirat Zentiva generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Viread.
The active substance in Tenofovir disoproxil Zentiva, tenofovir disoproxil, is a ‘prodrug' that is converted into tenofovir in the body. 
Zdravilna učinkovina zdravila Dizoproksiltenofovirat Zentiva, dizoproksiltenofovirat, je „predzdravilo“, ki se v telesu pretvori v tenofovir.
For practical information about using Tenofovir disoproxil Zentiva, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Dizoproksiltenofovirat Zentiva naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Therefore, the CHMP's view was that, as for Viread, the benefit outweighs the identified risk. 
Zato je menil, da njegove koristi enako kot pri zdravilu Viread odtehtajo znana tveganja.
Tenofovir disoproxil Zentiva is used in combination with other HIV medicines. 
Zdravilo Dizoproksiltenofovirat Zentiva se uporablja v kombinaciji z drugimi zdravili za zdravljenje okužbe z virusom HIV.
In HIV infection, it blocks the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses. 
Pri okužbi z virusom HIV zavira delovanje reverzne transkriptaze, tj. encima, ki ga tvori virus HIV in s pomočjo katerega lahko virus HIV okuži celice v telesu ter tvori nove viruse.
Other information about Tenofovir disoproxil Zentiva 
Druge informacije o zdravilu Dizoproksiltenofovirat Zentiva
Tenofovir disoproxil Zentiva tenofovir disoproxil 
Dizoproksiltenofovirat Zentiva dizoproksiltenofovirat
It is not intended to provide practical advice on how to use Tenofovir disoproxil Zentiva. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Why is Tenofovir disoproxil Zentiva approved? 
Zakaj je bilo zdravilo Dizoproksiltenofovirat Zentiva odobreno?
Tenofovir disoproxil Zentiva contains the active substance tenofovir disoproxil. 
Zdravilo Dizoproksiltenofovirat Zentiva vsebuje zdravilno učinkovino dizoproksiltenofovirat.
How is Tenofovir disoproxil Zentiva used? 
Kako se zdravilo Dizoproksiltenofovirat Zentiva uporablja?
How has Tenofovir disoproxil Zentiva been studied? 
Kako je bilo zdravilo Dizoproksiltenofovirat Zentiva raziskano?
Annex I List of medicinal products and presentations 
Seznam nacionalno odobrenih zdravil
Content (concentration) 
Stična ovojnina vsebina (koncentracija)
25 June 2015 
25. junij 2015
Outcome of procedures under Article 29(4) of Directive 2001/83/EC 
Izid postopka v skladu s členom 29(4) Direktive 2001/83/ES
The European Commission adopted a decision on this opinion on 25 June 2015. 
Evropska komisija je odločbo v zvezi s tem mnenjem sprejela 25. junija 2015.
The company wanted the authorisation to be recognised in Belgium, Germany, Luxembourg and the Netherlands (the ‘concerned Member States'). 
Družba je želela, da se dovoljenje za promet z zdravilom prizna v Belgiji, Nemčiji, Luksemburgu in Nizozemski (zadevnih državah članicah).
However, the Member States were not able to reach an agreement and the German and Dutch medicines regulatory agencies referred the matter to the CHMP for arbitration on 24 December 2014. 
Vendar države članice niso mogle doseči soglasja, zato sta nemška in nizozemska regulativna agencija za zdravila 24. decembra 2014 zadevo napotila na odbor CHMP v arbitražo.
The CHMP therefore recommended that the marketing authorisation be granted in the concerned Member States. 
Odbor CHMP je zato priporočil izdajo dovoljenja za promet z zdravilom v zadevnih državah članicah.
On 23 April 2015, the European Medicines Agency completed two arbitration procedures following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicines Merisone and Myoson (tolperisone). 
Evropska agencija za zdravila je 23. aprila 2015 zaključila dva arbitražna postopka po nesoglasju med državami članicami Evropske unije (EU) glede izdaje dovoljenj za promet z zdraviloma Merisone in Myoson (tolperizon).
Why were Merisone and Myoson reviewed? 
Zakaj sta bili zdravili Merisone in Myoson pregledani?
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Merisone and Myoson outweigh their risks, and the marketing authorisation granted in Hungary can be recognised in other Member States of the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravil Merisone in Myoson večje od z njima povezanih tveganj ter da se dovoljenje za promet, izdano na Madžarskem, lahko prizna v drugih državah članicah EU.
The grounds for the referral were that the bioequivalence studies had only been performed under fasting conditions. 
Napotitveni postopek je bil sprožen, ker so študije biološke enakovrednosti izvedli samo pri pogojih na tešče.
The exact way tolperisone works is not known, but it is thought to act in the brain and spinal cord to reduce the nerve impulses that make the muscles contract and become rigid. 
Natančen način delovanja tolperizona ni znan, vendar menijo, da deluje na možgane in hrbtenjačo, kjer zmanjša živčne imulze, ki povzročajo krčenje in togost mišic.
Merisone and Myoson are generic medicines based on a ‘reference medicine', Mydeton, which is already authorised in the EU. 
Merisone in Myoson sta generični zdravili, razviti na osnovi „referenčnega zdravila“ Mydeton, ki je že odobreno v EU.
Meditop Pharmaceutical Co. Ltd. submitted Merisone and Myoson for mutual recognition on the basis of their initial authorisation granted by Hungary on 18 March 2010. 
Družba Meditop Pharmaceutical Co. Ltd. je predložila vlogo za medsebojno priznavanje za zdravili Merisone in Myoson na podlagi prvotne odobritve na Madžarskem 18. marca 2010.
By reducing these impulses, tolperisone is believed to reduce muscle contraction and spacticity. 
Menijo, da tolperizon z zmanjšanjem teh impulzov zmanjša tudi krčenje mišic in spastičnost.
As the product information for Mydeton was recently updated to say that it should be taken with food, Germany and the Netherlands considered that a bioequivalence study under fed conditions would be required for the granting of a marketing authorisation. 
Ker so informacije o zdravilu Mydeton nedavno posodobili tako, da vključujejo navodilo, da ga je treba jemati skupaj s hrano, sta Nemčija in Nizozemska menili, da bi bilo treba za izdajo dovoljenja za promet z zdravilom izvesti študijo biološke enakovrednosti pri pogojih na poln želodec.
What are Merisone and Myoson? 
Kaj sta zdravili Merisone in Myoson?
Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that because of the characteristics of the active substance of Merisone and Myoson food will affect the absorption of the active substance in the same way as for Mydeton and no further studies are required. 
Na podlagi ocene trenutno razpoložljivih podatkov in znanstvene razprave znotraj odbora, je ta sklenil, da bo zaradi lastnosti zdravilne učinkovine v zdravilih Merisone in Myoson hrana vplivala na absorpcijo zdravilne učinkovine na enak način kot pri zdravilu Mydeton, zato niso potrebne dodatne študije.
Merisone and Myoson are identical medicines that are used to treat muscle spasms (involuntary contractions) and spasticity. 
Zdravili Merisone in Myoson sta enaki zdravili, ki se uporabljata za zdravljenje mišičnih spazmov (nezavednih krčev) in spastičnosti.
Because Merisone and Myoson are generic medicines, studies have been limited to tests to determine that they are bioequivalent to the reference medicine, Mydeton. 
Ker sta zdravili Merisone in Myoson generični zdravili, so bile študije omejene na preskuse za ugotavljanje, ali sta biološko enakovredni referenčnemu zdravilu Mydeton.
The active substance in Merisone and Myoson, tolperisone, is a centrally acting muscle relaxant. 
Zdravilna učinkovina v zdravilih Merisone in Myoson, tolperizon, je mišični relaksant, ki deluje na osrednje živčevje.
The CHMP therefore concluded that in the case of Merisone and Myoson the bioequivalence study in the fasting state is sufficient to conclude on the bioequivalence in both the fasting and fed states and that the benefits and risks of Merisone and Myoson can be taken to be the same as the reference medicine's. 
Odbor CHMP je zato zaključil, da je v primeru zdravil Merisone in Myoson študija biološke enakovrednosti pri pogojih na tešče zadostna za sklepanje glede biološke enakovrednosti pri pogojih na tešče in poln želodec in da je mogoče sklepati, da so koristi zdravil Merisone in Myoson enake kot pri referenčnem zdravilu.
- If you are very overweight. 
- če ste zelo debeli.
This serious allergic reaction needs immediate medical attention. 
Ta resna alergijska reakcija zahteva takojšnjo zdravniško pomoč.
QUALITATIVEAND QUANTITATIVE COMPOSITION 
KAKOVOSTNA IN KOLIČINSKA SESTAVA
This interference led to a false prolongation of PT and elevation of INR. 
Ta interferenca je povzročila lažno podaljšanje PČ in povečanje INR.
The duration of therapy should be in accordance with available official recommendations. 
Trajanje zdravljenja mora biti v skladu z razpoložljivimi uradnimi priporočili.
For blood or heart infections and skin infections your doctor will decide how long you should be treated. 
Pri okužbah krvi ali srca in okužbah kože se bo zdravnik odločil, kako dolgo vas bo treba zdraviti.
** See section 4.4. 
** glejte poglavje 4.4
However, from a microbiological point of view the product should be used immediately. 
Z mikrobiološkega stališča je treba zdravilo uporabiti takoj.
However, there is currently no evidence that a dose reduction is required (see section 5.2). 
Vendar pa trenutno ni nobenih dokazov, da je potrebno zmanjšanje odmerka (glejte poglavje 5.2).
The use of antibacterials may promote the overgrowth of non-susceptible micro-organisms. 
Uporaba antibiotikov lahko spodbuja prekomerno rast neobčutljivih mikroorganizmov.
The most common type of infection treated was wound infection (38% of patients), while 21% had major abscesses. 
Najpogostejša vrsta zdravljene okužbe je bila okužba rane (38 % bolnikov), medtem ko je imelo 21 % bolnikov večje abscese.
Important: Please refer to the Summary of Product Characteristics before prescribing. 
Pomembno: Prosimo, glejte povzetek glavnih značilnosti zdravila, preden predpišete zdravilo.
Up to 14 Days 
Do 14 dni
Mitochondrial loss/damage was also observed; however the role and significance of this finding in the overall pathology are unknown. 
Opazili so tudi izgubo/poškodbe mitohondrijev, vendar vloga in pomen te ugotovitve v okviru celotne patologije nista znana.
The prevalence of resistance may vary geographically and over time for selected species and local information on resistance is desirable, particularly when treating severe infections. 
Razširjenost odpornosti lahko pri izbranih vrstah geografsko in časovno variira in lokalne informacije o odpornosti so zaželene, še posebno kadar gre za zdravljenje hudih okužb.
A course of treatment usually lasts for 1 to 2 weeks for skin infections. 
Postopek zdravljenja pri okužbah kože običajno traja 1 do 2 tedna.
This mode of administration was only studied in healthy subjects. 
Ta način uporabe zdravila so proučevali samo pri zdravih osebah.
Consideration should be given to official guidance on the appropriate use of antibacterial agents. 
Upoštevati je treba uradne smernice za ustrezno uporabo protimikrobnih zdravil.
Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as not known. 
Ker o teh učinkih spontano poroča populacija neznane velikosti, ni mogoče zanesljivo določiti njihove pogostnosti, zato je ta opredeljena kot ''neznana''.
Detailed instructions for use and handling are given at the end of the leaflet. 
Podrobna navodila za uporabo in ravnanje z zdravilom so navedena na koncu navodila za uporabo.
Daptomycin is an antibacterial that can stop the growth of certain bacteria. 
Daptomicin je antibiotik, ki lahko zaustavi rast določenih bakterij.
- Patients should be reviewed regularly while on therapy for any signs or symptoms that might represent myopathy. 
• Bolnike je treba med zdravljenjem redno pregledovati glede kakršnihkoli znakov ali simptomov, ki bi lahko predstavljali miopatijo.